Flutiform ([fluticasone propionate + formoterol fumarate]; Vectura/Mundipharma/Kyorin) Drug Analysis 2018 - ResearchAndMarkets.com

DUBLIN--()--The "Drug Analysis: Flutiform" drug pipelines has been added to ResearchAndMarkets.com's offering.

Flutiform ([fluticasone propionate + formoterol fumarate]; Vectura/Mundipharma/Kyorin) is a pressurized metered-dose inhaler formulation which contains a combination of fluticasone propionate and formoterol. Fluticasone propionate is an inhaled corticosteroid which has potent anti-inflammatory activity when delivered by inhalation, while formoterol fumarate is a long-acting beta 2 agonist which acts as a bronchodilator.

Key Topics Covered:

1 Product Profiles

  • Flutiform: Asthma

List of Figures

Figure 1: Asthma - current and future market dynamics analysis

Figure 2: The author's drug assessment summary of Flutiform in asthma

Figure 3: The author's drug assessment summary of Flutiform in asthma

List of Tables

Table 1: Flutiform drug profile

Table 2: Flutiform pivotal trial data in asthma

Table 3: Flutiform Phase III trials in asthma

Table 4: Flutiform sales for asthma across Japan and the five major EU markets, by country ($m), 2017-26

Companies Mentioned

  • Vectura
  • Mundipharma
  • Kyorin

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/gdfrtp/flutiform?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Respiratory Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Respiratory Drugs